James D. Clark - 12 Feb 2024 Form 4 Insider Report for CVS HEALTH Corp (CVS)

Role
SVP, Cont & Chief Acct Officer
Signature
/s/ James D. Clark
Issuer symbol
CVS
Transactions as of
12 Feb 2024
Net transactions value
$0
Form type
4
Filing time
14 Feb 2024, 17:13:33 UTC
Previous filing
15 Dec 2023
Next filing
03 Apr 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CVS Common Stock Award $0 +2,452 +52% $0.000000 7,150 12 Feb 2024 Direct F1
holding CVS Common Stock (Restricted) 8,760 12 Feb 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding CVS Stock Option 9,050 12 Feb 2024 Common Stock 9,050 $78.05 Direct F2
holding CVS Stock Option 7,513 12 Feb 2024 Common Stock 7,513 $62.21 Direct F3
holding CVS Stock Option 24,240 12 Feb 2024 Common Stock 24,240 $54.19 Direct F4
holding CVS Stock Option 17,157 12 Feb 2024 Common Stock 17,157 $58.34 Direct F5, F6
holding CVS Stock Option 12,094 12 Feb 2024 Common Stock 12,094 $74.30 Direct F7
holding CVS Stock Option 6,756 12 Feb 2024 Common Stock 6,756 $101.09 Direct F8
holding CVS Stock Option 9,649 12 Feb 2024 Common Stock 9,649 $74.31 Direct F9
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares earned by the reporting person pursuant to certain performance stock units (the "PSUs"), which were granted to the reporting person under the Issuer's 2017 Incentive Compensation Plan on April 1, 2021. The PSUs were earned based on the attainment of certain performance metrics, which performance metrics were certified by the Management and Planning Committee of the Board of Directors of the Issuer on February 12, 2024.
F2 Options became exercisable in four equal annual installments beginning on 4/3/2018.
F3 Options became exercisable in four equal annual installments, commencing 4/1/2019.
F4 Options became exercisable in four equal annual installments, commencing 4/1/2020.
F5 The number of shares subject to the option were calculated using a 30-day average price.
F6 Options became exercisable in four equal annual installments, commencing 4/1/2021.
F7 Option became exercisable in four equal annual installments, commencing 4/1/2022.
F8 Option became exercisable in four equal installments, commencing 4/1/2023.
F9 Option becomes exercisable in four equal annual installments, commencing 4/1/2024.